ZR2 Sequential Immunochemotherapy for Newly Treated MCL

This study is testing a new drug combination for mantle cell lymphoma (MCL), a type of blood cancer, in patients who have never been treated before. The combination includes zanubrutinib, rituximab, and two chemotherapy regimens given in sequence. **You may be eligible if...** - You are between 18 and 75 years old - You have been newly diagnosed with mantle cell lymphoma confirmed by a biopsy (tissue test) - You have not received any previous treatment for this cancer - You are in good enough health to receive chemotherapy **You may NOT be eligible if...** - You have already received chemotherapy, radiation, or targeted therapy for MCL - You are outside the 18–75 age range - Your diagnosis was not confirmed by pathology testing Talk to your doctor to see if this trial is right for you.